Open AccessIs a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?
Author(s) -
Steven J. Rosansky,
Richard J. Glassock
Publication year - 2014
Publication title -
kidney international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.499
H-Index - 276
eISSN - 1523-1755
pISSN - 0085-2538
DOI - 10.1038/ki.2013.506
Subject(s) - surrogate endpoint , renal function , medicine , creatinine , intensive care medicine , end point , drug , clinical trial , clinical endpoint , endpoint determination , drug development , kidney disease , urology , randomized controlled trial , food and drug administration , pharmacology , geometry , mathematics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom